Canada Markets closed

iCo Therapeutics Inc. (ICO.V)

TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.0650+0.0100 (+18.18%)
At close: 3:52PM EST
Full screen
Previous Close0.0550
Open0.0500
Bid0.0650 x 0
Ask0.0700 x 0
Day's Range0.0500 - 0.0700
52 Week Range0.0200 - 0.0800
Volume6,239,268
Avg. Volume773,216
Market Cap9.994M
Beta (5Y Monthly)2.70
PE Ratio (TTM)N/A
EPS (TTM)-0.0120
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • iCo Therapeutics Inc. Proposes to Re-Price Warrants
    Newsfile

    iCo Therapeutics Inc. Proposes to Re-Price Warrants

    Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), announces that they are submitting an application to the TSX Venture Exchange to amend the exercise price of 66,200,000 previously granted common share purchase warrants (the "Warrants") issued pursuant to a private placement of 25,000,000 units that was completed over several tranches from January 31, 2019 to March 4, 2019 (the "Spring 2019 Private ...

  • iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical
    Newsfile

    iCo Therapeutics Announces Joint Development of iCo-019 with Skymount Medical

    Vancouver, British Columbia--(Newsfile Corp. - December 31, 2020) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), iCo Therapeutics, Inc. ("iCo") and Skymount Medical, Inc. ("Skymount") announced today that they have entered into a non-binding Memorandum of Understanding to develop iCo-019, iCo's oral Amphotericin B formulation. Skymount will initially commit up to $US 550,000 for pre-clinical work targeting the use of iCo-019 as a therapeutic product for infections relating to COVID-19."I ...

  • iCo Therapeutics Announces Third Quarter 2020 Financial Results
    Newsfile

    iCo Therapeutics Announces Third Quarter 2020 Financial Results

    Vancouver, British Columbia--(Newsfile Corp. - November 24, 2020) -  iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company"), today reported financial results for the quarter ended September 30, 2020. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").Stated William Jarosz, CEO of iCo Therapeutics Inc., "We have aggressively continued to contain our operating expenses quarter over quarter and year over year. This has allowed ...